Roche’s preeclampsia test helps to predict this life-threatening condition in pregnant women at risk
10 December 2014 | By Roche
New data demonstrate high prognostic value of Elecsys blood test...
List view / Grid view
News
Pricing for new drugs lacks transparency
10 December 2014 | By The Royal Society of Medicine
The system that allows patients rapid access to expensive new treatments lacks transparency and penalises small and low-income countries unable to negotiate lower prices with pharmaceutical manufacturers...
The Prince of Wales marks the 10th anniversary of International Health Partners as they launch EURMED
9 December 2014 | By Janssen
International Health Partners (IHP) in partnership with Banco Farmaceutico and Action Medeor has launched EURMED; a unique industry collaboration that enables the donation of medicines for disaster relief and humanitarian aid.
Roche presents data for hemophilia A therapy ACE910
9 December 2014 | By Roche
Roche presented data from a first-in-patient study of the novel humanised bispecific antibody ACE910 (RG6013) in hemophilia A patients during the 56th American Society of Hematology (ASH) Annual Meeting...
Scottish Medicines Consortium accepts use of Alimta (pemetrexed) for treatment of non-small cell lung cancer
9 December 2014 | By Eli Lilly and Company
On 8th December 2014, the Scottish Medicines Consortium accepted for use within NHS Scotland Alimta (pemetrexed) monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer (other than predominantly squamous cell histology) in patients whose disease has not progressed immediately following platinum-based chemotherapy...
Lilly and Incyte announce positive top-line results from Phase 3 trial of baricitinib in moderate to severe rheumatoid arthritis
Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) today announce that the Phase 3 RA-BEACON study of the investigational medicine baricitinib met its primary endpoint of improved ACR20 response compared to placebo after 12 weeks of treatment.
Ergomed’s partner Aeterna Zentaris signs agreement with Sinopharm A-Think for zoptarelin doxorubicin in China
9 December 2014 | By Ergomed plc
Ergomed plc has announced that Aeterna Zentaris has signed an exclusive licence and technology transfer agreement with Sinopharm A-Think for the Chinese, Hong Kong and Macau markets for zoptarelin doxorubicin which is in Phase 3 development for treating endometrial cancer...
Roche to present clinical data from six different medicines at ASH
9 December 2014 | By Roche
Presentations include data on Roche’s broad portfolio of hematology medicines as well as emerging investigational agents including ACE910 (RG6013) in hemophilia A...
New data show specific antidote idarucizumab* reverses dabigatran-induced anticoagulation also in elderly and renally impaired volunteers
9 December 2014 | By Boehringer Ingelheim
New data demonstrate that a five-minute infusion of the investigational specific antidote idarucizumab led to immediate, complete and sustained reversal of the anticoagulant effect of Pradaxa® (dabigatran etexilate)...
NovoEight®, phase 3 data show reduction in annualised bleeding rate over time in people with haemophilia A
9 December 2014 | By Novo Nordisk
Novo Nordisk announced a new analysis of phase 3 data demonstrating people with haemophilia A who had the highest annualised bleeding rate (ABR) during initial treatment with NovoEight® (turoctocog alfa) showed the largest reduction in bleeding over the duration of treatment...
SMC says ‘yes’ to new blood cancer drug
9 December 2014 | By Roche
Victory for Scottish NHS patients as SMC accepts Gazyvaro™ (obinutuzumab) for treatment of most common adult leukaemia...
Roche launches next-generation viral load testing assays for new molecular diagnostic platforms in markets accepting the CE mark
9 December 2014 | By Roche
cobas HIV-1 and HCV assays offer unparalleled performance on cobas 6800/8800 Systems...
GSK presents asthma data that shows no additional clinical efficacy benefits for ICS-treatments with a small particle size
9 December 2014 | By GSK
GSK presented data at the British Thoracic Society meeting from a systematic analysis of 25 randomised control studies (RCTs), including a meta-analysis of three key efficacy outcomes, which explored the potential impact of the particle size of different ICS-containing asthma medicines, including Seretide/Advair (salmeterol/fluticasone proprionate) on patient outcomes...
Daiichi Sankyo launches new formulation of LIXIANA® 60 mg Tablets (edoxaban) in Japan
8 December 2014 | By Daiichi Sankyo
Daiichi Sankyo Company, Limited announced that it has launched a new formulation of LIXIANA®60 mg Tablets...
Phase III data shows Sandoz’ investigational biosimilar filgrastim has similar safety and efficacy as Amgen’s NEUPOGEN®
8 December 2014 | By Novartis
Sandoz, a Novartis company, announced Phase III data that demonstrated similarity of its investigational biosimilar filgrastim compared to the US-licensed reference product, Amgen's NEUPOGEN ® (filgrastim) in the prevention of severe neutropenia in patients with breast cancer receiving neoadjuvant myelosuppressive chemotherapy...
